• Hamed Atarodi, Abdolreza Pazouki, Barmak Gholizadeh, Reza Karami, Ali Kabir, Ghazal Sadri, Radwan Kassir, and Mohammad Kermansaravi.
• Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Rasool-e-Akram Hospital, Tehran, Iran.
• J Res Med Sci. 2022 Jan 1; 27: 7676.

BackgroundA large liver size is a factor that may increase the difficulty of bariatric surgery (BS) and unwanted complications. Some agents have been used to decrease the liver size before BS. Silymarin has been used as an antioxidant agent to improve liver function tests. This study was designed to evaluate the effects of silymarin on liver dimensions, function, and lipid profile.Materials And MethodsA double-blind randomized clinical trial was performed on 56 patients. The patients were divided into silymarin and placebo groups. Blood samples and sonographic examinations were taken from the patients before and 4 weeks after the administration of the silymarin or placebo. In the first group, 140 mg silymarin was prescribed every 8 h for 4 weeks, and the other group received placebo in the same way with the same tablet shape. After the completion of the 4-week treatment, laboratory tests and ultrasonography were carried out again.ResultsThirty-nine (69.6%) patients were female with a mean body mass index (BMI) of 46.2 kg/m2 and a mean age of 36.8 years. Most of the patients had a compliance of 80% and higher. The analysis did not show any significant difference in aspartate transaminase, alkaline transaminase, liver size, cholesterol, and triglyceride changes among the silymarin and placebo groups. BMI loss was slightly higher in the silymarin group although the difference was not statistically significant.ConclusionThe present findings show that silymarin administration for 4 weeks does not affect liver size and function, but further evaluations should be carried out on the subject.Copyright: © 2022 Journal of Research in Medical Sciences.

5 keywords...

hide…